Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

被引:0
|
作者
Winnie Y. Sohn
Anthony A. Portale
Isidro B. Salusky
Hao Zhang
Lucy L. Yan
Bella Ertik
Shahnaz Shahinfar
Edward Lee
Bastian Dehmel
Bradley A. Warady
机构
[1] Amgen,
[2] Inc.,undefined
[3] UCSF Benioff Children’s Hospital,undefined
[4] David Geffen School of Medicine at UCLA,undefined
[5] S. Shahinfar Consulting and Childrens Hospital of Philadelphia,undefined
[6] Children’s Mercy Hospital,undefined
来源
Pediatric Nephrology | 2019年 / 34卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The original version of this article unfortunately contained three mistakes. In Table 1, the last line under “Key Inclusion Criteria” should read “Normal or clinically acceptable ECGs at screening and at day − 1.” In addition, the abbreviation “IP” in the legend to Table 1 stands for “investigational product.”
引用
收藏
页码:739 / 740
页数:1
相关论文
共 50 条
  • [31] A PHASE 1, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1850 IN ADULTS WITH HYPOPHOSPHATASIA
    Dahir, K.
    Dunn, D.
    Mitter, S.
    Hasan, J.
    Shannon, A.
    Pan, W.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S191 - S192
  • [32] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
    Shakeri-Nejad, Kasra
    Aslanis, Vassilios
    Veldandi, Uday Kiran
    Gardin, Anne
    Zaehringer, Andreas
    Dodman, Angela
    Su, Zhenzhong
    Legangneux, Eric
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 41 - 53
  • [33] An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine
    Baird-Bellaire, Susan
    Behrle, Jessica A.
    Parker, Vernon D.
    Patat, Alain
    Paul, Jeffrey
    Nichols, Alice I.
    CLINICAL THERAPEUTICS, 2013, 35 (06) : 782 - 794
  • [34] An open-label, exploratory, limited dose escalation study to evaluate the pharmacokinetics, safety and tolerability of gemcitabine hydrochloride oral formulation in subjects with malignant tumors
    Gabrail, Nashat Y.
    Ghamande, Sharad A.
    Silverman, Michael H.
    Smith, Carrie L.
    Ho, Hsiang-Ling
    Huang, Chia-Tsung
    Hsueh, Shu-Ping
    Lin, Chia-Li
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Bola Tayo
    Lesley Taylor
    Farhad Sahebkar
    Gilmour Morrison
    Clinical Pharmacokinetics, 2020, 59 : 747 - 755
  • [36] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Tayo, Bola
    Taylor, Lesley
    Sahebkar, Farhad
    Morrison, Gilmour
    CLINICAL PHARMACOKINETICS, 2020, 59 (06) : 747 - 755
  • [37] Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study
    Sohn, Winnie
    Winkle, Peter
    Neutel, Joel
    Wu, You
    Jabari, Freeman
    Terrio, Caitlin
    Varrieur, Tracy
    Wang, Jingying
    Hellawell, Jennifer
    CLINICAL THERAPEUTICS, 2022, 44 (09) : 1237 - 1247
  • [38] Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
    Lee, C.
    Tang, Y.
    Schroeder, C.
    Zhang, J.
    Nguyen-Cleary, T.
    Mullin, S.
    Ma, M.
    Lyon, N.
    Grundy, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S321 - S322
  • [39] A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
    Schwertschlag, Ullrich
    Shi, William Dongfang
    Perry, Robert
    Ayesu, Kwabena
    Wu, Roy
    Liu, Jerry
    Lin, JinSying
    Jin, Adam
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4082 - 4083
  • [40] Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
    Manuel Santamaria
    Olaf Neth
    Jo A. Douglass
    Gergely Krivan
    Robin Kobbe
    Ewa Bernatowska
    Sofia Grigoriadou
    Claire Bethune
    Anita Chandra
    Gerd Horneff
    Michael Borte
    Anja Sonnenschein
    Pavlina Kralickova
    Silvia Sánchez Ramón
    Daman D. Langguth
    Luis Ignacio Gonzalez‑Granado
    Laia Alsina
    Montse Querolt
    Rhonda Griffin
    Carrie Hames
    Elsa Mondou
    Jeffrey Price
    Ana Sanz
    Jiang Lin
    Journal of Clinical Immunology, 2022, 42 : 512 - 513